There are currently 78 ongoing clinical trials involving Amyloidosis
Of the 78 trials,23 trials are in Phase II
Furthermore, 17 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Amyloidosis, a Metabolic Disorder. The highest number of ongoing clinical trials involving Amyloidosis is in North America. Asia-Pacific and Europe are among some of the other prominent regions involved in Amyloidosis -related drug trials.
Alnylam Pharmaceuticals Inc: The leading ongoing Amyloidosis -related clinical trials sponsor
Alnylam Pharmaceuticals Inc, the United States of America-based pharmaceutical company, is the top sponsor for Amyloidosis-related ongoing clinical trials.
Pfizer Inc, Memorial Sloan Kettering Cancer Center, Caelum Biosciences Inc, Eidos Therapeutics Inc, Ionis Pharmaceuticals Inc, and Barbara Ann Karmanos Cancer Institute are a few other notable sponsors involving Amyloidosis.
A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Amyloidosis
Tafamidis meglumine (Vyndaqel, Fx-1006A, PF-06291826), Canakinumab (Ilaris/ Lasprona/ Vyncro), and Patisiran (Onpattro) are among the key marketed drugs involving Amyloidosis.
Tafamidis meglumine (Vyndaqel, Fx-1006A, PF-06291826), a Transthyretin (ATTR or Prealbumin or TBPA or TTR) Inhibitor, is indicated for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment and for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. The drug is marketed globally including in the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including Pfizer Inc. Tafamidis meglumine was first approved in 2011 and formulated as soft gelatin capsules for oral route of administration.
Canakinumab (Ilaris/ Lasprona/ Vyncro), an Interleukin 1 Beta Inhibitor, is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes, in adults and children 4 years of age and older including Familial Cold Autoinflammatory Syndrome, tumor necrosis factor receptor-associated periodic syndrome, hyper immunoglobulin D syndrome/mevalonate kinase deficiency, Familial Mediterranean Fever, Muckle-Wells Syndrome and pancreatic cancer. The drug is marketed globally including the US, the UK, Australia, France, and Germany by several prominent pharma giants including Novartis Pharmaceuticals Corp. Canakinumab was first approved in 2009 and formulated as a powder for solution and solution for a subcutaneous route of administration
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward